FilingReader Intelligence
Shen Lian Bio approves 2024 results, share repurchase
May 26, 2025 at 12:00 PM UTC•By FilingReader AI
** Shanghai Shen Lian Biomedical Corporation (SSE: 688098) announced the resolutions passed at its 2024 Annual General Meeting, including the approval of the 2024 financial results and the annual profit distribution plan, as well as a share repurchase program. Shareholders ratified the board's and supervisors' reports, endorsing the company's financial performance and strategic direction.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
Supplementary Source Documents
SSE:688098•Shanghai Stock Exchange
Animal Health
News Alerts
Get instant email alerts when Shanghai Shen Lian Biomedical Corporation publishes news
Free account required • Unsubscribe anytime